Biotech Stock News (RXII) (REGN) (SURG) (VRX) (ACAD)

Rxi Pharmaceuticals (NASDAQ:RXII) On August 31, 2015 Rxi announced that the 30-day review period for its IND of RXI-109 for scarring of macular degeneration has passed its review period and the IND is now active. The whole point of the 30-day review period is for the FDA to look at pre-clinical data and conclude whether … Read more

Biotech Stock News (AAVL) (AERI) (AGN) (KYTH) (RHHBY) (REGN) (PFE) (NVS)

Avalanche Biotech (NASDAQ:AAVL) Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were … Read more